Mecamylamine attenuates dexamethasone-induced anxiety-like behavior in association with brain derived neurotrophic factor upregulation in rat brains

Neuropharmacology

Volumn 61, Issue 1-2, 2011, Pages 276-282

  Park, Dong Ik ^a   Kim, Hong Gi ^a   Jung, Woo Ram ^a   Shin, Min Kyoo ^a   Kim, Kil Lyong ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Anxiety; Brain derived neurotrophic factor; Dexamethasone; Elevated plus maze; Mecamylamine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DEXAMETHASONE; MECAMYLAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAZE TEST; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; DEXAMETHASONE; HUMANS; MALE; MECAMYLAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79957801746     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.04.013     Document Type: Article

References (35)

1. Andreasen, J.T., Redrobe, J.P., 2009. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav. Pharmacol. 20 (3), 286-295.
2. Caldefie-Chézet, F., Poulin, A., Enreille-Leger, A., Vasson, M.P., 2005. Troglitazone reduces leptinemia during experimental dexamethasone-induced stress. Horm. Metab. Res. 37, 164-171.
3. Choi, D.C., Maguschak, K.A., Ye, K., Jang, S.W., Myers, K.M., Ressler, K.J., 2010. Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc. Natl. Acad. Sci. U.S.A. 107 (6), 2675-2680. 9.
4. Cdh1 activation and neuroblastoma SH-SY5Y differentiation. Oncogene, 1-6.
5. David, D.J., Samuels, B.A., Rainer, Q., Wang, J.W., Marsteller, D., Mendez, I., Drew, M., Craig, D.A., Guiard, B.P., Guilloux, J.P., Artymyshyn, R.P., Gardier, A.M., Gerald, C., Antonijevic, I.A., Leonardo, E.D., Hen, R., 2009. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62, 479-493.
6. Debruyne, D., Sobrio, F., Hinschberger, A., Camsonne, R., Coquerel, A., Barré, L., 2003. Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. J. Pharm. Sci. 92 (5), 1051-1057.
7. Dwivedi, Y., Rizavi, H.S., Conley, R.R., Roberts, R.C., Tamminga, C.A., Pandey, G.N., Tamminga Pandey, Ghanshyam N., 2003. Altered Gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 60, 804-815.
8. Fedorov, N.B., Benson, L.C., Graef, J., Lippiello, P.M., Bencherif, M., 2009. Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition. J. Pharmacol. Exp. Ther. 328, 525-532.
9. File, S.E., Vellucci, S.V., Wendlandt, S., 1979. Corticosterone - an anxiogenic or an anxiolytic agent? J. Pharm. Pharmacol. 31 (5), 300-305.
10. Gass, P., Rive, M.A., 2007. CREB, neurogenesis and depression. Bioassays 29 (10), 957-961. (Pubitemid 47522836)
11. Hiramatsu, M., Miwa, M., Hashimoto, K., Kawai, S., Nomura, N., 2008. Nociceptin/ orphanin FQ reverses mecamylamine-induced learning and memory impairment as well as decrease in hippocampal acetylcholine release in the rat. Brain Res. 1195, 96-103.
12. Jamali, B., Roodsari, M.S., Soleymani, Z., Faizi, M., Shafaghi, B., Kobarfard, F., 2009. Synthesis of a quaternary bis derivative of imipramine as a novel compound with potential anti-enuretic effect. J. Pharm. Pharmacol. 61 (9), 1229-1232.
13. Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.M., 2002. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 109 (2), 143-148. (Pubitemid 34258493)
14. Larsen, M.H., Hay-Schmidt, A., Rønn, L.C., Mikkelsen, J.D., 2008. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants. Eur. J. Pharmacol. 578 (2-3), 114-122. Jan 14.
15. Lippiello, P.M., Beaver, J.S., Gatto, G.J., James, J.W., Jordan, K.G., Traina, V.M., Xie, J., Bencherif, M., 2008. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci. Ther. 14 (4), 266-277.
16. Martinowich, K., Manji, H., Lu, B., 2007. New insights into BDNF function in depression and anxiety. Nat. Neurosci. Neurosci 10 (9), 1089-1093.
17. Molendijk, M.L., Bus, B.A., Spinhoven, P., Penninx, B.W., Kenis, G., Prickaerts, J., Voshaar, R.O., Elzinga, B.M., 2010. Serum levels of brain-derived neurotrophic factor in major depressive disorder: stateetrait issues, clinical features and pharmacological treatment. Mol. Psychiatry, 1-8.
18. Molteni, R., Calabrese, F., Bedogni, F., Tongiorgi, E., Fumagalli, F., Racagni, G., Riva, M.A., 2006. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int. J.Neuropsychopharmacol. 9, 307-317.
19. Newman, M.B., Manresa, J.J., Sanberg, P.R., Shytle, R.D., 2002. Anxiolytic effects of mecamylamine in two animal models of anxiety. Exp. Clin. Psychopharmacol. 10 (1), 18-25.
20. Newton, S.S., Thome, J.,Wallace, T.L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E.J., Duman, R.S., 2002. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J. Neurosci. 22 (24), 10883-10890. (Pubitemid 36005163)
21. Olson, Mikel L., Olson, Emily A., Qualls, Jacob H., Stratton, Jessica J., Harding, Joseph W., Wright, John W., 2004. Norleucine1-angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 25, 233-241.
22. Pellow, S., Chopin, P., File, S.E., Briley, M., 1985. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14, 149-167. (Pubitemid 16239568)
23. Rabenstein, R.L., Caldarone, B.J., Picciotto, M.R., 2006. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology 189, 395-401. (Pubitemid 44772820)
24. Russo-Neustadt, A.A., Alejandre, H., Garcia, C., Ivy, A.S., Chen, M.J., 2004. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 29, 2189-2199. (Pubitemid 39578909)
25. Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., Ernfors, P., Castrén, E., 2003. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23 (1), 349-357. (Pubitemid 36050437)
26. Schmidt, H.D., Duman, R.S., 2010. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology, 1-14.
27. Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S., Iyo, M., 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 1 (54), 70-75. (Pubitemid 36776725)
28. Shirayama, Y., Chen, A.C., Nakagawa, S., Russell, D.S., Duman, R.S., 2002. Brainderived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (8), 3251-3261. (Pubitemid 35379212)
29. Shytle, R.D., Silver, A.A., Sanberg, P.R., 2000. Comorbid bipolar disorder in tourette syndrome responds to nicotinic receptor antagonist, mecamylamine (Inversine). Biol. Psychiatry 48, 1028-1031.
30. Shytle, R.D., Silver, A.A., Sheehan, K.H., Sheehan, D.V., Sanberg, P.R., 2002a. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence. Depress. Anxiety 16 (3), 89-92. (Pubitemid 35334663)
31. Shytle, R.D., Silver, A.A., Lukas, R.J., Newman, M.B., Sheehan, D.V., Sanberg, P.R., 2002b. Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry 7, 525-535.
32. Urani, A., Chourbaji, S., Gass, P., 2005. Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci. Biobehav. Rev. 29, 805-828.
33. Vafaei, A.A., Rashidy-Pour, A., Taherian, A.A., 2008. Peripheral injection of dexamethasone modulates anxiety related behaiviors in mice: an interaction with opioidergic neurons. Pak. J. Pharm. Sci. 21, 285-289.
34. Yagasaki, Y., Numakawa, T., Kumamaru, E., Hayashi, T., Su, T.P., Kunugi, H., 2006. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. 281 (18), 12941-12949.
35. Yamamoto, S., Morinobu, S., Takei, S., Fuchikami, M., Matsuki, A., Yamawaki, S., Liberzon, I., 2009. Single prolonged stress: toward an animal model of post-traumatic stress disorder. Depress. Anxiety 26, 1110-1117.